Key result
Elevated sIL-2R levels normalize over 2 months after successful PTCA in stable angina.
Why the study?
The role of T lymphocyte activation in stable angina pectoris patients undergoing PTCA and the influence of PTCA on this activation were not well characterized.
Does percutaneous transluminal coronary angioplasty reduce T lymphocyte activation (sIL-2R levels) in patients with stable angina pectoris?
Observational (n=39)
Does percutaneous transluminal coronary angioplasty reduce T lymphocyte activation (sIL-2R levels) in patients with stable angina pectoris?
T lymphocytes are activated in a subset of patients with stable angina, and elevated sIL-2R levels decrease toward normal following successful PTCA.
Answers are grounded in this paper and cite their sources.
T-cell activation marker may decline after PTCA in select stable angina patients; leaves open its role as a follow-up biomarker.
BACKGROUND: Inflammatory reactions have an important part in atherosclerosis. Smooth muscle cells, endothelial cells, monocytes, and T lymphocytes are actively involved. The purpose of this study was to assess whether T lymphocytes are activated in patients with stable angina pectoris who are candidates for a percutaneous transluminal coronary angioplasty (PTCA) and the influence of PTCA on this process. METHODS AND RESULTS: Twenty-four patients participated in the study. All were 40- to 60-year-old men, and all but one underwent successful PTCA. Blood samples were taken 1 day before PTCA and 1 week, 1 month, and 2 months after. Two groups of patients were detected: group A, 11 patients who had high levels of soluble interleukin-2 receptor (sIL-2R) before PTCA that decreased toward normal during the follow-up period in most of them; and group B, 13 patients who did not have elevated sIL-2R levels before PTCA and in whom sIL-2R levels did not change after the procedure. Group C consisted of 15 healthy men whose sIL-2R levels were in the normal range (control subjects). CONCLUSIONS: (1) T lymphocytes are activated in stable angina patients. (2) The level of sIL-2R can be a reliable laboratory marker for follow-up of patients after PTCA, especially those with high sIL-2R levels before the procedure.
No takes yet. Share an insight, caveat, or question.
Blum et al. (1995) conducted an observational in Stable angina pectoris (n=39). Percutaneous transluminal coronary angioplasty (PTCA) vs. Healthy controls and pre-PTCA baseline was evaluated on Soluble interleukin-2 receptor (sIL-2R) levels. Among 24 men with stable angina undergoing PTCA, 11 had high pre-procedural soluble interleukin-2 receptor levels that decreased toward normal during the 2-month follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: